Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8302 Phase 1 SAD/MAD in Healthy Japanese Subjects
NCT03361540Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP8302 in underactive bladder (UAB) (7 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of adverse events, Safety assessed by vital signs: Body temperature and 5 more. Started Nov 2017; status: completed.
02
Drugs
ASP8302
03
Conditions
underactive bladder (UAB)
Beyond the preview
Go deeper on NCT03361540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361540.